A 50 Week Extension to: A Multicenter, Randomized, Double-Blind Factorial Study of the Co-Administration of MK-0431 and Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus

Merck Sharp & Dohme Limited0 个研究点目标入组 900 人开始时间: 2005年3月16日最近更新: 2019年6月30日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 900

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•036 BASE STUDY:
•Patients who meet the criteria listed below will be recruited for enrollment into the study. All laboratory measurements are to be performed after an overnight fast =12 hours in duration.
•a.Patient has type 2 diabetes mellitus (T2DM).
•b.Patient is =18 and =78 years of age.
•c.Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.
•d.Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.
•e.Patient is a male, or a female who is highly unlikely to conceive, as indicated by at least one yes” answer to the following questions:
•1)Patient is a male.
•2)Patient is a surgically sterilized female.
•3)Patient is a postmenopausal female =45 years of age with >2 years since last menses.
•4)Patient is a non-sterilized premenopausal female and agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy (either 2 barrier methods or a barrier method plus a hormonal contraceptive method) or (2) abstain from heterosexual activity throughout the study starting with Visit 1 and for 14 days after the last dose of study medication. Refer to Section I.E.12.a. for description of acceptable methods of contraception.
•f.Patient meets one of the following criteria as indicated by a yes” answer to one of the following:
•1)Patient is currently not on an antihyperglycemic agent (off therapy for =8 weeks) and has a Visit 1/Screening Visit HbA1c =7.5% and =11%.
•Patient is in 1 of the following 3 categories AND based upon review of the patient’s current diet, medical regimen, and Visit 1/Screening Visit HbA1c, patient is considered by the investigator to be likely to meet Visit 3 inclusion criterion of HbA1c =7.5% to =11% with diet/exercise counseling:
•2)Patient is currently not on an antihyperglycemic agent (off therapy for =8 weeks) and has a Visit 1/Screening Visit HbA1c >11%.
•3)Patient is currently on antihyperglycemic agent monotherapy or dual oral combination therapy and has a Visit 1/Screening Visit HbA1c =7% and =10%.
•4)Patient is currently on dual oral combination therapy (which contains at least one agent dosed at >50% maximal labeled dose), has Visit 1/Screening Visit HbA1c =6.5% and <7%, and has been approved by the Merck clinical monitor.
•NOTE: Patients currently not on an antihyperglycemic agent, but off therapy for <8 weeks, may be enrolled following discussion with and approval by the Merck Clinical Monitor.
•g.HbA1c =7.5% and =11% measured at Visit 3. NOTE: Once a patient has initiated placebo run-in at Visit 3, if the Visit 3 HbA1c is not within the Visit 3 HbA1c inclusion criterion, a single repeat measurement may be performed at the discretion of the investigator. If repeat value meets Visit 3 HbA1c inclusion criterion, patient may continue in study.
•h.Patient has =75% compliance (as measured by tablet count) with placebo treatment during run-in.
•036 EXTENSION STUDY:
•All laboratory measurements are to be performed after an overnight fast =12 hours in duration.

排除标准

•036 BASE STUDY
•See the BASE STUDY protocol for comprehensive list and additional clarification.
•a. Patient has a history of type 1 diabetes or ketoacidosis.
•b. Patient required insulin within the prior 8 weeks.
•c. Patient has an hypersensitivity contraindication to biguanide medication.
•d. Patient has a serum ALT or AST >2.0-fold the Upper Limit of Normal. Note: Patients whose serum ALT or AST exceeds this limit may be retested one time if the investigator does not believe the value reflects the patient’s clinical status.
•e. Serum creatinine 123.8 µmol/L in men and 114.9 µmol/L in women or estimated creatinine clearance (using Cockcroft-Gault formula) <60 mL/min.
•f. Patient has cirrhosis or active liver disease or active nephropathy or chronic progressive neuromuscular disorder or any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.
•g. Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months or has any of the following disorders within the past 6 months: 1) Acute coronary syndrome. 2). Coronary artery intervention. 3) Stroke or transient ischemic neurological disorder. 4) Congestive heart failure treated with pharmacologic therapy. h. Patient is HIV positive.
•i. Patient has a clinically important hematological disorder.
•j. Patient has a history of malignancy. Exceptions: 1) patients with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate; 2) patients with other malignancies which have been successfully treated =5 years prior to screening, where in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of screening; and 3) patients who, in the joint opinion of homa, malthe Merck medical monitor and investigator, are highly unlikely to sustain a recurrence during the duration of the study. However, patients with a history of leukemia, lympignant melanoma, myeloproliferative disease, or renal cell carcinoma are ineligible for the study regardless of the time since treatment, and in such cases, no exceptions will apply.
•k. Patient has a history of alcohol or drug abuse within the past year 3 years.
•l. Patient has a fasting plasma glucose consistently >270 mg/dL (14.99 mmol/L) and is not considered likely to improve glycemic control with diet and exercise counseling.
•036 EXTENSION STUDY
•At Visit 14
•a.Patient has developed any medical condition or disorder that, in the opinion of the investigator or Merck Clinical Monitor, might pose a risk to the patient or would make the use of metformin contraindicated based upon the product label in that country (refer to Appendix 11).
•b.Patient is on or likely to require an excluded medication (ie. Non-study antihyperglycemic medication, immunosuppressive/immunomodulating agent, etc. (See Appendix 1).

研究者

发起方

Merck Sharp & Dohme Limited

相似试验

进行中（未招募）

1 期

A 52-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 52 weeks treatment with LAF237 50 mg bid to metformin up to 1000 mg bid in drug naïve patients with type 2 diabetesType II Diabetes

EUCTR2004-002136-25-ESovartis Pharma S.A

进行中（未招募）

不适用

EUCTR2004-002136-25-GBovartis Pharmaceuticals UK Ltd530

已完成

不适用

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)-E10 Insulin-dependent diabetes mellitus-E14 Unspecified diabetes mellitusInsulin-dependent diabetes mellitusUnspecified diabetes mellitusE10E14

PER-110-07MERCK SHARP & DOHME PERU S.R.L.,

进行中（未招募）

不适用

A 28-week extension to a multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with LAF237 50 mg bid to rosiglitazone 8 mg qd in drug naïve patients with type 2 diabetesExtensión de 28 semanas del estudio multicéntrico, aleatorizado, doble ciego, con control activo que compara el efecto de 24 semanas de tratamiento con 50 mg bid de LAF237 frente a 8 mg qd de rosiglitazona en pacientes naive con diabetes Tipo 2.Diabetes Mellitus II

EUCTR2004-002644-10-ESovartis Farmaceutica S.A.660

已完成

不适用

SAFETY AND EFFICACY STUDY OF QVM149 IN ASTHMATIC PATIENTS

PER-024-16OVARTIS BIOSCIENSES PERU S.A.,26